In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with Xpovio (selinexor) following systemic therapy may prolong progression-free survival, according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology Plenary Series.
In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
